Tranexamic Acid Use Is Associated With Lower Rates of Transfusion in Patients Undergoing Revision Total Hip Arthroplasty for Periprosthetic Joint Infection Authors: Sahil S. Telang, Julian Wier, Pranit Kumaran, Steven H. Liu, Jacob Becerra, Jay R. Lieberman, Nathanael D. Heckmann Published: 2026 ABSTRACT BackgroundWhile tranexamic acid (TXA) is widely used in primary total hip arthroplasty (THA), it has not been studied extensively during revision THA for periprosthetic joint infection (PJI). Since revision procedures for infection are associated with greater intraoperative blood loss and a higher likelihood of transfusion, investigation of TXA use in first-stage revision THA for PJI is warranted to define its impact on postoperative bleeding risk, transfusion requirements, and safety profile.MethodsQuerying a large healthcare database, we identified adult patients between 2016 and 2023 undergoing stage-one revision THA for PJI. Patients who received TXA were subsequently identified. Propensity score matching was used to balance cohorts. Mixed-effects logistic regression models were used to assess primary outcome, transfusion. Secondary outcomes included postoperative bleeding outcomes, wound complications, deep vein thrombosis, and pulmonary embolism.ResultsAfter 1:1 propensity matching, 10,404 patients that had explanation of their THA and placement of an antibiotic spacer were included, with all hospital characteristics, patient demographics, and comorbidities demonstrating standardized mean differences <0.10. TXA-treated patients had significantly lower rates of postoperative transfusion (15.94% vs 17.78%; adjusted odds ratio = 0.86, 95% confidence interval [CI] = 0.76-0.99, P = .030) and wound complications (16.69% vs 22.72%; odds ratio = 0.66, 95% confidence interval = 0.59-0.73). Similar rates were found for aggregate bleeding complications, deep vein thrombosis, and pulmonary embolism in both cohorts.ConclusionsTXA is associated with a reduction in postoperative transfusion and wound complications in patients undergoing revision THA for PJI. Introduction Tranexamic acid (TXA) is widely used in primary total hip arthroplasty (THA) practice due to level I evidence supporting its safety and efficacy in reducing perioperative blood loss and transfusion requirements [[1], [2], [3], [4], [5], [6], [7]]. However, there remains a paucity of data regarding its use in revision THA performed for periprosthetic joint infection (PJI). Notably, the use of TXA for patients undergoing revision THA for PJI has not been widely adopted. First-stage revision THA for PJI requires extensive debridement, implant removal, and placement of antibiotic spacers, resulting in greater intraoperative blood loss, longer operative duration, and higher transfusion rates than primary THA patients [[8], [9], [10]]. Prior literature has reported that up to 81% of patients undergoing staged revision THA for PJI receive allogeneic transfusions, with a mean transfusion volume of 3.6 ± 1.8 units for first-stage revision [8]. Given the increased blood loss associated with revision THA procedures for PJI, TXA utilization may be an important component of perioperative blood conserving strategies as allogeneic transfusion has been associated with higher rates of postoperative infection and venous thromboembolism (VTE) [[11], [12], [13], [14], [15], [16]]. Moreover, the presence of active infection induces a systemic proinflammatory state that further heightens VTE risk compared with both primary and aseptic revision arthroplasty [[17], [18], [19]]. In light of these competing risks, namely heightened bleeding potential, transfusion-related complications, and infection-induced thrombotic potential, the role of TXA in PJI-related revision THA merits further examination. As such, the aim of the present study was to evaluate the effect of TXA administration on bleeding complications and transfusion rates in patients undergoing first-stage revision THA for PJI. We hypothesized that TXA use would be associated with lower postoperative transfusion rates and bleeding complications, without an associated increase in VTE risk. Material and methods The Premier Healthcare Database (PHD) was queried to identify adult patients (aged ≥18 years) who underwent spacer placement for PJI of the hip from January 2016 to December 2023. The PHD is an all-payer claims database that includes approximately 25% of all procedures performed in the United States, containing information regarding hospital characteristics and patient demographics. Additionally, comprehensive patient-specific billing records, including impact charges and administered medications during hospital admission are coded using PHD-specific charge codes, International Classification of Disease 10th Revision (ICD-10) codes, and Current Procedural Terminology (CPT) codes. Cohort selection Patients were identified for the diagnosis of PJI or other deep infection of the joint using ICD-10 diagnosis codes. (Supplemental Table 1) Revision procedures and antibiotic spacer placement were identified using ICD-10 procedure coding system and CPT codes. (Supplemental Table 2) Charge data from day of surgery was examined to determine if antibiotic-loaded cement containing either vancomycin, gentamicin, or tobramycin powders was implanted. (Supplemental Table 3) To accurately capture true antibiotic spacer placement, patients with charges reflecting ˂2000 mg of vancomycin, 2400 mg of gentamicin, or 2400 mg of tobramycin were excluded. Direct charges for antibiotic spacers or cement were also included. (Supplemental Table 3). Adult patients undergoing stage-one antibiotic spacer placement for PJI following THA were included in the final cohort. Patients were then stratified using PHD-specific billing codes if they had received oral and/or intravenous TXA perioperatively. Study outcomes The primary outcome of the study was the 90-day odds of postoperative transfusion. Secondary outcomes included 90-day odds of postoperative bleeding complications (eg, hemorrhage, acute anemia, hematoma, and hemarthrosis), VTE disease (PE and DVT), and wound complications (wound dehiscence, seroma, and superficial surgical site infection [SSI]). The 90-day postoperative outcomes were captured through any subsequent inpatient readmission, emergency department visit, or outpatient encounter within the same health system within 90 days of the index surgical admission. Patients were identified using a PHD-defined unique, longitudinal identifier that enables tracking across multiple encounters within the same health system. Outcomes were defined using ICD-10 diagnosis codes. (Supplemental Table 4) Postoperative transfusion was defined as administration of either whole or packed red blood cells during the 90-day postoperative period. Propensity score matching A propensity matching algorithm was applied to reduce selection bias and enhance causal inferences. Patients who were administered TXA were matched 1:1 to patients who were not administered TXA. Nearest-neighbor matching without replacement using a standard caliper of 0.2 times the standard deviation of the propensity score was employed. Postmatch covariate balance was assessed with standardized mean difference values being <0.10. Multivariable regression analysis was used to calculate propensity scores, employing all available comorbidity, laboratory, and demographic data. Covariates for matching were selected through a least absolute shrinkage and selection operator. Regularization parameters (λ) were chosen using 3 difference criteria: initially λ was chosen via cross-validation to minimize prediction error, and then selected based on the Bayesian Information Criterion to improve model selection and finally an adaptive least absolute shrinkage and selection operator model was implemented, using adaptive weights to improve the consistency of variable selection [20,21]. Only covariates that appeared in all 3 models were selected for the final model. Covariates included in the propensity score model are provided in Supplemental Table 5. Model performance was evaluated using the area under the receiver operating characteristic curve (0.6885) and the Hosmer–Lemeshow goodness-of-fit test (P = .218), indicating adequate model discrimination and calibration. (Supplemental Fig. 2). Statistical analysis Hospital characteristics, patient demographics, frailty via the Johns Hopkins Adjusted Clinical Groups Frailty Index, and comorbidities per the Elixhauser system were reported as mean (standard deviation) or frequency (proportion). A Charlson Comorbidity Index was also calculated. Categorical variables were assessed using chi-squared, while continuous variables were assessed using independent t-tests or Mann–Whitney tests where appropriate. Mixed-effects multivariable logistic regression was employed to account for any residual confounding not captured by the propensity for TXA treatment using surgeon identifier as the random intercept to account for surgeon specific variation. Minimization of Akaike’s Information Criterion followed by Bayesian Information Criterion was utilized to optimize the model. The intraclass correlation coefficient value ˃0.05 was considered to indicate non-negligible clustering, justifying the use of mixed-effects modeling to account for correlated observations within clusters. Statistical significance was set at P < .05. All statistical analyses were performed using Stata (version 17.0; StataCorp LLC, College Station, TX). Results In total, 16,715 patients were identified who underwent definitive, component removal, and spacer implementation, including 10,281 (61.38%) who received TXA and 6434 (38.62%) who did not. Following 1:1 matching based, 10,404 patients who underwent first-stage revision THA for PJI were included, with 5202 patients who received TXA (TXA[+]) and 5202 without TXA exposure (TXA[−]). A patient selection flowchart detailing the sequential exclusion criteria and final matched cohort is provided in Supplemental Figure 1. Both cohorts were similar with respect to age (TXA[+]: 66.87 years vs TXA[−]: 67.06), length of stay (TXA[+]: 9.49 days vs TXA[−]: 9.67 days), and sex (% male, TXA[+]: 48.19% vs TXA[−]: 47.85%). In addition, both cohorts had similar rates of postoperative VTE chemoprophylaxis utilization, including aspirin (TXA[+]: 30.14% vs TXA[−]: 28.37%), low-molecular-weight heparin (TXA[+]: 47.35% vs TXA[−]: 48.56%), and direct oral anticoagulants (TXA[+]: 10.71% vs TXA[−]: 10.46%). Furthermore, both cohorts had comparable Charlson Comorbidity Index scores (TXA[+]: 3.69 vs TXA[−]: 3.74) (Tables 1 and 2). Patients within the TXA cohort had an average dose of TXA of 2.27 ± 3.34 g, with 75.0% of patients receiving ≤2 g.Table 1Demographic characteristics for matched cohorts based on TXA exposure.DemographicTXA+N = 5202TXA-N = 5202SMDAverageStandard deviationAverageStandard deviationAge (years)66.8712.0667.0612.720.015Length of stay (days)9.4879.729.678.770.019NumberPercentNumberPercentMale sex0.021 Yes250748.19%248947.85%Race0.038 Asian310.60%310.60% Black4127.92%4037.75% Other2615.02%3005.77% White432483.12%427982.26% Hispanic1743.34%1893.63%Marital status0.098 Married235045.17%227443.71% Other3536.79%4929.46% Single249948.04%243646.83%Payer category0.006 Medicare349767.22%349767.22% Medicaid4658.94%4578.79% Private106820.53%107420.65% Other1723.31%1743.34%Emergency admission0.042 Yes321461.78%331963.80%Preoperative transfusion0.007 Yes59311.40%60511.63%Antithrombotic agent0.054 Low-molecular-weight heparin246347.35%252648.56% Aspirin156830.14%147628.37% Heparin4328.30%4889.38% Direct oral anti-coagulant55710.71%54410.46% Warfarin1703.27%1593.06%Bed size0.117 <1002745.27%1723.31% 100-19967913.05%70413.53% 200-29980615.49%81715.71% 300-39983015.96%77914.98% 400-49960311.59%71813.80% >500201038.64%201238.68%Rural (vs urban)0.007 Urban477991.87%476991.68%Teaching status0.009 Yes291656.06%293856.48%Region0.140 Midwest127324.47%115222.15% Northeast73114.05%98818.99% South228843.98%225643.37% West91017.49%80615.49%SMD, standardized mean difference.Table 2Comorbidities characteristics for matched cohorts based on TXA exposure.CormorbidityTXA+N = 5202TXA-N = 5202SMDAverageStandard deviationAverageStandard deviationCharlson Comorbidity Index3.692.153.742.230.023N%N%Frail133325.62%138126.55%0.021Congestive heart failure79015.19%84416.22%0.029Coronary artery disease3476.67%3526.77%0.004Arrhythmia111021.34%122623.57%0.053Heart valve disease881.69%871.67%0.001Pulmonary circulation disorders1823.50%2013.86%0.019Chronic pulmonary disease129324.86%122223.49%0.032Peripheral vascular disease3596.90%3647.00%0.004Hypertension258649.71%257949.58%0.003Complicated hypertension122323.51%128524.70%0.028Cerebrovascular accident4428.50%4658.94%0.016Hemiplegia/paraplegia210.40%380.73%0.044Other neurological disorders58511.25%61411.80%0.017Diabetes, uncomplicated60611.65%63112.13%0.015Diabetes, complicated86616.65%80215.42%0.034Hypothyroidism97118.67%103819.95%0.033Renal failure93818.03%95818.42%0.010Liver disease3186.11%3035.82%0.012Chronic peptic ulcer disease360.69%310.60%0.012Blood loss anemia1042.00%1102.11%0.008Deficiency anemia4288.23%4258.17%0.002Coagulopathy4107.88%4208.07%0.007Venous thromboembolism72413.92%72914.01%0.003Fluid and electrolyte disorders185835.72%189136.35%0.013Rheumatic disease4208.07%4348.34%0.010HIV/AIDS230.44%260.50%0.008Lymphoma340.65%350.67%0.002Solid tumor891.71%1092.10%0.028Metastatic cancer531.02%561.08%0.006Obesity158930.55%154629.72%0.018Weight loss4999.59%5069.73%0.005Alcohol abuse2815.40%2665.11%0.013Drug abuse3416.56%2885.54%0.043Psychoses611.17%721.38%0.019Depression129024.80%121323.32%0.035 Table 1Demographic characteristics for matched cohorts based on TXA exposure.DemographicTXA+N = 5202TXA-N = 5202SMDAverageStandard deviationAverageStandard deviationAge (years)66.8712.0667.0612.720.015Length of stay (days)9.4879.729.678.770.019NumberPercentNumberPercentMale sex0.021 Yes250748.19%248947.85%Race0.038 Asian310.60%310.60% Black4127.92%4037.75% Other2615.02%3005.77% White432483.12%427982.26% Hispanic1743.34%1893.63%Marital status0.098 Married235045.17%227443.71% Other3536.79%4929.46% Single249948.04%243646.83%Payer category0.006 Medicare349767.22%349767.22% Medicaid4658.94%4578.79% Private106820.53%107420.65% Other1723.31%1743.34%Emergency admission0.042 Yes321461.78%331963.80%Preoperative transfusion0.007 Yes59311.40%60511.63%Antithrombotic agent0.054 Low-molecular-weight heparin246347.35%252648.56% Aspirin156830.14%147628.37% Heparin4328.30%4889.38% Direct oral anti-coagulant55710.71%54410.46% Warfarin1703.27%1593.06%Bed size0.117 <1002745.27%1723.31% 100-19967913.05%70413.53% 200-29980615.49%81715.71% 300-39983015.96%77914.98% 400-49960311.59%71813.80% >500201038.64%201238.68%Rural (vs urban)0.007 Urban477991.87%476991.68%Teaching status0.009 Yes291656.06%293856.48%Region0.140 Midwest127324.47%115222.15% Northeast73114.05%98818.99% South228843.98%225643.37% West91017.49%80615.49%SMD, standardized mean difference. Demographic characteristics for matched cohorts based on TXA exposure. SMD, standardized mean difference. Table 2Comorbidities characteristics for matched cohorts based on TXA exposure.CormorbidityTXA+N = 5202TXA-N = 5202SMDAverageStandard deviationAverageStandard deviationCharlson Comorbidity Index3.692.153.742.230.023N%N%Frail133325.62%138126.55%0.021Congestive heart failure79015.19%84416.22%0.029Coronary artery disease3476.67%3526.77%0.004Arrhythmia111021.34%122623.57%0.053Heart valve disease881.69%871.67%0.001Pulmonary circulation disorders1823.50%2013.86%0.019Chronic pulmonary disease129324.86%122223.49%0.032Peripheral vascular disease3596.90%3647.00%0.004Hypertension258649.71%257949.58%0.003Complicated hypertension122323.51%128524.70%0.028Cerebrovascular accident4428.50%4658.94%0.016Hemiplegia/paraplegia210.40%380.73%0.044Other neurological disorders58511.25%61411.80%0.017Diabetes, uncomplicated60611.65%63112.13%0.015Diabetes, complicated86616.65%80215.42%0.034Hypothyroidism97118.67%103819.95%0.033Renal failure93818.03%95818.42%0.010Liver disease3186.11%3035.82%0.012Chronic peptic ulcer disease360.69%310.60%0.012Blood loss anemia1042.00%1102.11%0.008Deficiency anemia4288.23%4258.17%0.002Coagulopathy4107.88%4208.07%0.007Venous thromboembolism72413.92%72914.01%0.003Fluid and electrolyte disorders185835.72%189136.35%0.013Rheumatic disease4208.07%4348.34%0.010HIV/AIDS230.44%260.50%0.008Lymphoma340.65%350.67%0.002Solid tumor891.71%1092.10%0.028Metastatic cancer531.02%561.08%0.006Obesity158930.55%154629.72%0.018Weight loss4999.59%5069.73%0.005Alcohol abuse2815.40%2665.11%0.013Drug abuse3416.56%2885.54%0.043Psychoses611.17%721.38%0.019Depression129024.80%121323.32%0.035 Comorbidities characteristics for matched cohorts based on TXA exposure. Study Outcomes Patients who received TXA demonstrated a significant decrease in rates of transfusion (TXA[+]:15.94% vs TXA[−]:17.78%, P = .012) and wound complications (TXA[+]:16.69% vs TXA[−]:22.72%, P = .012). Following multivariable regression, TXA(+) patients demonstrated significantly decreased risk of transfusion (adjusted odds ratio [aOR]:0.86, 95% confidence interval [CI]: 0.76-0.99, P = .030) and wound complications (aOR:0.59, 95% CI: 0.59-0.73, P < .001). Both cohorts demonstrated similar rates of postoperative bleeding complications, VTE, DVT, and PE on univariate and multivariable analysis (Table 3). The rates of individual composite for aggregate bleeding and wound complications are tabulated in Supplemental Table 6.Table 3Univariate and mixed-effects logistic regression for study outcomes between matched cohorts.90-day OutcomeTXA + N = 5202TXA-N = 5202P valueMultivariable regressionNumberPercentNumberPercentaOR95% CI lower bound95% CI upper boundICCP valuePostoperative venous thromboembolism2114.06%2244.31%.5240.970.791.180.092.753Postoperative wound complication86816.69%118222.72%<.0010.660.590.730.089<.001Postoperative transfusion82915.94%92517.78%.0120.860.760.990.353.030Postoperative bleeding complications267551.42%262650.48%.3371.050.951.150.288.342Deep vein thrombosis1583.04%1743.34%.3720.930.741.160.417.510Pulmonary embolism761.46%701.35%.6171.130.811.570.030.480ICC, intraclass correlation coefficient.Bolded values indicate statistical significance. Table 3Univariate and mixed-effects logistic regression for study outcomes between matched cohorts.90-day OutcomeTXA + N = 5202TXA-N = 5202P valueMultivariable regressionNumberPercentNumberPercentaOR95% CI lower bound95% CI upper boundICCP valuePostoperative venous thromboembolism2114.06%2244.31%.5240.970.791.180.092.753Postoperative wound complication86816.69%118222.72%<.0010.660.590.730.089<.001Postoperative transfusion82915.94%92517.78%.0120.860.760.990.353.030Postoperative bleeding complications267551.42%262650.48%.3371.050.951.150.288.342Deep vein thrombosis1583.04%1743.34%.3720.930.741.160.417.510Pulmonary embolism761.46%701.35%.6171.130.811.570.030.480ICC, intraclass correlation coefficient.Bolded values indicate statistical significance. Univariate and mixed-effects logistic regression for study outcomes between matched cohorts. ICC, intraclass correlation coefficient. Bolded values indicate statistical significance. Discussion In the present study of over 10,000 patients undergoing first-stage revision THA for PJI, TXA use was associated with a significantly reduced risk of postoperative transfusion and wound complications. There was no statistically significant difference in the rates of postoperative VTE complications between patients who did and did not receive TXA. Furthermore, the present study also identified a substantial subset of patients in whom TXA was not administered, revealing that the use of TXA in PJI cases may be less routine than generally perceived. This variation in practice pattern highlights the need for analyses like the present investigation, and its use of rigorous statistical methodology may offer the most accurate estimate to date of TXA's transfusion-sparing effect in this specific patient population. While TXA’s hemostatic benefits has been well-established in primary arthroplasty patients, data on its administration in PJI populations remain limited largely to small sized case series [2,8,[22], [23], [24]]. In a retrospective analysis of 163 patients undergoing first-stage revision for PJI, Abdelaziz et al observed that TXA administration was associated with a 12.8% absolute reduction in transfusion rates (58.3 vs 71.1%) [15]. Similarly, Goet et al., analyzed 276 first-stage revision THA for PJI retrospectively, and found that TXA use was associated with a 0.36-fold reduction in adjusted odds of postoperative transfusion, though this difference was not statistically significant [8]. In the largest meta-analysis investigating TXA administration in revision arthroplasty, authors observed among 930 patients, of which 501 received TXA, that recipients required a mean 0.44 fewer units of transfused blood than nonrecipients [25]. These prior investigations are limited by small sample sizes, single-center designs, or inclusion of mixed patient populations encompassing aseptic and PJI, as well as revision knee and hip cases. In contrast, the present study provides specificity by focusing exclusively on first-stage revision THA for PJI in a large multicenter cohort. Furthermore, the present analysis utilized a robust matching analysis and mixed-effects modeling, which together better account for different bleeding profiles across varying postoperative anticoagulation agents, surgeon-specific practice patterns, and indication bias, as TXA may have be preferentially given to patients deemed to be at lower VTE risk [8,26]. As such, the employed statistical framework builds on prior arthroplasty literature by providing a more precise evaluation of TXA’s effect on transfusion rates in patients undergoing revision THA for PJI. The reduction in transfusion rates reported in this study are clinically meaningful, especially in light of the well-documented risks associated with allogeneic blood transfusion. Administration of allogeneic blood products are an established risk factor for postoperative infection in TJA patients [13,14,[27], [28], [29], [30], [31]]. Specifically, exposure to allogeneic blood is associated with an increased risk of surgical site infection, impaired wound healing, as well as both superficial and deep infections among arthroplasty patients [[11], [12], [13], [14],16]. Transfusion-related immunomodulation impairs host immune defenses via the release of immunomodulators from stored red blood cells [[32], [33], [34], [35]]. Consequently, the release of immunosuppressive cytokines leads to suppression of macrophage phagocytosis, impaired neutrophil chemotaxis, and downregulation of T-cell proliferation [[32], [33], [34]]. Therefore, host clearance of pathogens and within healing surgical sites is diminished, thereby facilitating a heightened infection risk. By minimizing exposure to allogeneic blood transfusion, TXA utilization in PJI patients may potentially help preserve innate immune surveillance and reduce the risk for infection-related sequelae. Beyond a reduction in transfusion rates, the present analysis also observed that TXA administration was associated with a significantly reduced risk of postoperative wound complications. Patients undergoing revision THA for PJI tend to exhibit an elevated baseline risk for poor wound healing due to greater comorbidity burden, chronic inflammation, and tissue hypoxia from prior bacterial biofilm, collectively impairing angiogenesis, collagen deposition, and epithelialization [[36], [37], [38], [39], [40]]. TXA may mitigate these risks by promoting hemostatic stabilization and minimizing hematoma formation, which in turn may shorten drainage duration and lowers the incidence of wound dehiscence and SSI, factors known to elevate the risk of re-revision and reinfection [15,[41], [42], [43], [44]]. The findings of this study are not without limitations. As with any retrospective database study, the use of ICD and CPT coding introduces the potential for coding inaccuracies and patient misclassification. To minimize miscoding bias, cohort identification did not rely solely on diagnosis and procedure codes. Charge-level data were also used to validate true antibiotic spacer placement based on antibiotic type and quantity administered, ensuring greater specificity in cohort selection. However, there may exist residual confounding due to the inability of coding data to reliably account for intraoperative variables such as the use of osteotomies or other surgical techniques that may affect the associated bleeding and VTE risk of individual procedures. Importantly, we do not believe this residual bias would disproportionately impact either cohort. Additionally, composite wound and bleeding complications were selected as study endpoints, rather than assessed as individual subcomponents. While these composites capture a wide clinical spectrum of outcomes influenced by TXA, the individual subcomponents vary in severity and clinical interpretation. For example, incidence of acute anemia within the bleeding composite outcome may capture expected postoperative hemoglobin decline rather than clinically actionable bleeding events. Furthermore, as the present analysis was performed utilizing a retrospective administrative database, granular measures such as exact intraoperative blood loss were unavailable to corroborate these diagnosis codes. Nevertheless, transfusion requirement was used as the primary outcome measure, which arguably represents the most clinically meaningful surrogate for intraoperative blood loss. Moreover, reoperation due to bleeding or wound complications was not included within the present analysis, as we were unable to reliably identify them during the 90-day postoperative window. Finally, the present analysis did not account for the dose of TXA provided to each patient, as dosing regimens differ across surgeons, hospital systems, and on the individual patient level due to indication bias. Rather, the present study aimed to provide a broad assessment of TXA’s overall efficacy and safety in this complex patient population. Future investigations defining the optimal dosing and administration strategy specific to PJI-related revision procedures would provide further guidance for arthroplasty surgeons. Conclusions The present study represents, to our knowledge, the largest evaluation of the effect of TXA on postoperative transfusion and wound complication rates among patients undergoing the first-stage revision THA for PJI. The application of a rigorous matching strategy and mixed-effects modeling affords a robust estimation of TXA’s effect size, quantifying the magnitude of its benefit in a high-risk arthroplasty population susceptible to transfusion. Conflict of interest Nathanael Heckmann receives royalties from Corin USA; is a paid consultant for Intellijoint Surgical, MicroPort Orthopaedics, Corin USA, and Zimmer; holds stock or stock options in Intellijoint Surgical; and is a board member in AAOS, AJRR, AAHKS, the Knee Society, and the Hip Society. Jay R. Lieberman receives royalties from DePuy: A Johnson & Johnson Company; receives royalties, financial or other material support from Saunders/Mosby-Elsevier; is a paid consultant for DePuy: A Johnson & Johnson Company; holds stock or stock option in BD Surgiphor and Hip Innovations Technologies; and serves as a board member of AAOS, the Hip Society, Musculoskeletal Transplant Foundation, Western Orthopaedic Association. All other authors declare no potential conflicts of interest. For full disclosure statements, refer to https://doi.org/10.1016/j.artd.2026.102106. CRediT authorship contribution statement Sahil S. Telang: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Conceptualization. Julian Wier: Writing – review & editing, Writing – original draft, Investigation, Formal analysis, Conceptualization. Pranit Kumaran: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis. Steven H. Liu: Writing – review & editing, Writing – original draft, Methodology, Investigation. Jacob Becerra: Writing – review & editing, Writing – original draft, Methodology, Formal analysis. Jay R. Lieberman: Writing – review & editing, Supervision, Formal analysis, Conceptualization. Nathanael D. Heckmann: Writing – review & editing, Methodology, Formal analysis, Conceptualization.